beyond the ratio of 1 : 10. A show cause notice has since been issued to M/s. Abbot Laboratories for failure to fulfil the condition.

(f) According to the Company production commenced in December. 1984 and production upto 7th November, 1985 was 700 Kgs.

Sales turn over of Panama Industries and Laboratories

1559. SHRI (MOLANA) ASRARUL HAQ: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 19 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether it is a fact that the sales turn over of Panama Industries and Laboratories is around Eight to Ten Crores per annum;

(b) if so, what was the annual sales turn over of this company during the last three years. year-wise;

(c) when did it come to Government's notice that this company is marketing their products without price approval;

(d) names of the products which fall under price control;

(e) why no action under provision 29 of Drugs Price Control Order, 1979 has been taken against the company when it was found that the company has violated the provisions of Drugs Price Control Order, 1979; and

(f) by when penal action will be taken against the company?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (f) It came to the notice of the Government in early 1984 that M|s. Panama industries and Labs. were marketing their formulations like proxyvon, Buta Proxyvon, Spasmo Broxyvin etc. even after crossing the limit of Rs. 50 lakhs in sales turnover without price approval. After notice was issued to M|s. Panama Industries and Labs. for taking action under Para 29 of the Drugs (Prices Control) Order, 1979 reply from their successor in business namely, M|s. Mujhardt Chemicals was received. M|s. Mujhardt Chemicals has since reported that they are no longer manufacturing pharmaceuticals preparations. Action is, however, on to identify the manufaturers of these products and to initiate action against such manufacturer in acordance with due procedure of Law.

Price of Erythromycin

1560. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 162 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) what was the price fixed for Erythromycin and its salts from basic stages as well as from TIOC;

(b) whether it is a fact that TIOC is penultimate;

(c) if so, what was the cost of production from basic stages as well as from TIOC;

(d) what was the price taken per Kg. of Erythromycin and its salts for fixing the prices of formulations based on the production from TIOC and from basic stages separately;

(e) whether the purchase invoices were verified and if so, what are the prices fixed for formulations based on purchase invoices along with names of the companies and purchase price per Kg. in each case; and

(f) what are the names of five major selling brands based on Erythromycin and its salts along with price fixed of each pack strength and what was the price taken of bulk drug while fixing the price of each brand?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Price now in vogue, for Erythromycin and its salts produced ex-Fermentation Stage and ex-TIOC under Drugs (Price Control) Order, 1979 is given below:—

(1) Erythromycin Base.....2220.62
(2) Erythromycin Estilat.....1992.50
(3) Erythromycin Stearate....1648.00

(b) Yes, Sir.

(c) Cost of production ex-basic state of fermentation and ex-TIOC was equalised by levying a customs duty of 140 per cent *ad-valorem* on TIOC.

(d) to (f) Prices of formulations are based on the notified price of the bulk drugs under Drugs (Prices Control) Order, 1979. Leader prices of Erythromycin based formulations as notified by the Government are given in the attached Statement (*See below*). The major brands of these formulations are:—

1. Erythrocin
2. Althrocin
3. E-mycin
4. Thromycin
5. Eltocin

Statement

(Rs.)

Sl. No.	Name of the formulation and strength	Pack size	Leader price excluding excise duty
1	Erythromycm Stearate Tabs. 100 mg/tablet.	10's 100's bottle	7·27 45·40
2	Erthromycin Stearate Tabs. 250 mg/tablets	10's	17·34
3	Erythromycin Estolate Tabs. 100 mg/tablet	10's	8·02
4	Erythromycin Estolate Tabs. 250 mg/tablet.	10's	18·02

Sales turn over of M/s. Capsulation Services

1561. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 165 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) what was the sales turn over of M/s. Capsulation Services during the last three years, year-wise;

(b) what are the products being produced by them;

(c) what is the price charged by them for each pack, strength of Cephalexin Capsules from Glaxo and at what price Glaxo is selling to the consumers;

(d) what are the reasons for getting the product manufactured from M/s. Capsulation Service by Glaxo when the company is permitted to manufacture the formulations based on their own produced bulk drug;

(e) whether M/s. Capsulation Service is producing Cephalexin Capsules from imported bulk drug; and

(f) if so, who is importing the bulk drug; and from whom and what is the quantity imported during the last two years, year-wise alongwith CIF price and source of import?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (f) Information to the extent available would be collected and laid on the Table of the Rajya Sabha.

Negligible production of some antibiotics by IDPL

1562. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 171 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) what are the reasons for negligible production of Erythromycin. Doxycline and Semi-synthetic Penicillines such as Ampicillin and Amoxicilline despite the fact that the technologies were purchased for the production of these drugs by IDPL;